Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer
Personalization of lung cancer treatment requires predictive biomarkers that have been validated by correlation between tumor features and outcomes after therapy. Several mutations have been identified in the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC). Mutations in this gene are considered an important predictor of response to EGFR tyrosine kinase inhibitors (TKIs) with 70–80% of NSCLC patients receiving substantial beneﬁts from this targeted therapy (1). The EGFR mutation is both a predictive and prognostic factor of EGFR-TKI therapy outcome (1,2). Testing for these mutations in all patients with recurrent or metastatic lung adenocarcinoma is therefore recommended for standard practice.